Feb 6 (Reuters) - Medical equipment maker Mettler-Toledo International MTD.N forecast annual profit above estimates on Thursday, banking on strong demand for its laboratory instruments used in drug development.
The company had said in November that market conditions remain soft, especially in China, but added that it expects them to gradually improve throughout 2025.
Some analysts are hopeful that a recent interest rate cut by the Federal Reserve could improve funding for small- and medium-sized biotechs, as borrowing costs might ease and boost demand.
The Columbus, Ohio-based company forecast 2025 adjusted profit in the range of $42.35 to $43.00 per share, compared to analysts' estimates of $42.13 per share, as per data compiled by LSEG.
Mettler-Toledo said its profit forecast includes headwinds from shipping delays and a stronger dollar.
The firm's fourth-quarter sales rose 12% to $1.05 billion, beating estimates of $1.01 billion.
On an adjusted basis, Mettler-Toledo earned a profit of $12.41 per share for the quarter ending December 31, topping analysts' estimates of $11.71 each.
The company had also said that it would benefit from the prior-year shipping delays in the fourth quarter.
(Reporting by Christy Santhosh and Sneha S K in Bengaluru; Editing by Alan Barona)
((Christy.Santhosh@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。